In a context where ZDV is still massively prescribed and most patients initiate ART at an advanced stage of the disease with low CD4 count, the implementation of the WHO recommendation will be crucial in order to reduce the risk of severe neutropenia. This evidence concerns the gene CD4 and neutropenia.